Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1996-10-08
2001-05-08
Huff, Sheela (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
06228837
ABSTRACT:
Throughout this application, various references are referred to within parenthesis. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end each series of experiments.
BACKGROUND OF THE INVENTION
Tumor vasculature is uniquely subject to the influence of products derived from the neoplastic cells. This may underlie the altered reactivity of vessels in certain tumors to catecholamines (1), tumor necrosis factor (TNF), flavone acetic acid (2), as well as other agents. To identify tumor-derived mediators which alter vascular function, the experiments described herein focussed on murine methylcholanthrene A (meth A)-induced fibrosarcomas. In vivo, this tumor is sensitive to TNF, and infusion of the cytokine at low concentrations results in vascular compromise localized to the neoplastic lesions with early thrombosis/hemorrhage in the vessels and increased vascular permeability, and rater regression of the tumor (3-7). In contrast, cultured meth A tumor cells are relatively insensitive to TNF (3,8). This suggests that tumor-derived mediators, potentially acting at the level of the endothelium, a central regulator of vascular tone, permeability and thrombogenicity, could be important in host-tumor interactions.
These considerations have led to the study of supernatants of meth A fibrosarcoma cells in order to identify soluble factors which alter endothelial functions. Recently, the purification of an apparently unique polypeptide, M
T
≈40,000, which alters endothelial and monocyte properties (Endothelial cell and Monocyte Activating Polypeptide, EMAP I) was reported (9-10). Reported here are the purification, N-terminal sequence, and characterization of another novel polypeptide from the same meth A fibrosarcoma supernatants, which alters endothelial and monocyte functions, induces the migration of monocytes and granulocytes, and induces an inflammatory response in the mouse footpad model. Because of these properties, this second polypeptide derived from meth A cells is termed endothelial-monocyte activating polypeptide II (EMAP II).
A prominent characteristic of immunogenic tumors is the presence of an inflammatory infiltrate surrounding the neoplastic lesion (103). One potentially important mechanism through which tumors modulate the host response is through the production of cytokines activating host effector cells, including mononuclear phagocytes (MPs), polymorphonuclear leukocytes (PMNs), and endothelial cells (ECs) (4-7). Using the murine methylcholanthrene A-induced fibrosarcomas (meth A) as a model system, three polypeptides with cytokine-like activities were identified (5-7). One of these is the murine homologue of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) (6) which modulates properties of ECs, including growth and induction of the procoagulant cofactor tissue factor, and MPs, including cell migration and tissue factor expression (8-13). In addition, two distinct polypeptides from meth A-conditioned medium termed endothelial-monocyte activating polypeptides I and II were isolated (5,7). EMAP II, a novel ≈20 kDa polypeptide which has recently been cloned and is not a member of previously described cytokine/chemokine families, has multiple effects on ECs, Mps, and PMNs in vitro, and induces an acute inflammatory response upon subcutaneous injection into mice (7).
Protein sequence data from the N-terminal region of EMAP II (residues #10-20) indicated a close relationship to von Willebrand factor antigen II (residues #480-490; 14-15), a molecule released by platelets and ECs along with von Willebrand factor (16-17). Pilot studies with purified von Willebrand antigen II showed that it had cytokine-like properties resembling EMAP II (18), leading to speculation that the region of strong sequence homology between the two molecules might mediate effects on target cells. Consistent with the possibility that the N-terminal position of EMAP II might be involved in its interaction with target cells is an homology to residues #31-37 of Interleukin (IL) 8, which includes the Glu-Leu-Arg motif associated with receptor binding and neutrophil activation by IL-8 (19-21). This study reports the synthesis of a series of peptides based on the N-terminal sequence of EMAP II (residues #6-20), and used these to perform experiments on cultured MPs and PMNs, and to inject into mouse footpads. The results support the hypothesis that this region of the molecule contributes to the functional activity of EMAP II. The N-terminal EMAP II-derived peptides interact with specific, potentially novel cellular binding sites, and may define a new ligand-receptor interaction important in tumor vasculature and inflammation.
SUMMARY OF THE INVENTION
This invention provides a purified endothelial monocyte activating polypeptide II (EMAP II).
This invention further provides a method of obtaining purified endothelial monocyte activating polypeptide II (EMAP II).
This invention provides a method of obtaining antibodies to purified endothelial monocyte activating polypeptide II (EMAP II).
This invention provides a method of detecting the presence of purified endothelial monocyte activating polypeptide II (EMAP II) in a sample.
This invention also provides an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRIVT and are in the same relative positions.
This invention further provides a method of detecting the presence in a sample of effector cell activating protein.
This invention provides a method of treating a tumor in a subject comprising administering an effective dose of endothelial monocyte activating polypeptide II (EMAP II).
REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4481137 (1984-11-01), Ohnishi et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4785077 (1988-11-01), Kornbluth et al.
patent: 4863727 (1989-09-01), Zimmerman et al.
patent: 4900724 (1990-02-01), Kato et al.
patent: 4980160 (1990-12-01), Goldberg et al.
Gura et al, Science vol. 278 p. 1041, Nov. 1997.*
DuBois, Appella et al.,Cancer Research(Nov. 1980) 40:4204-4208.
DuBois, Law, and Appella,Proc. Natl. Acad. Sci.-USA(Dec. 1982) 79:7669-7673.
Goding, et al.Journal of Immunological Method(1980) 39285-39308.
Goodman, et al.,Basic Clinical ImmunologyFudenberg et al. (Eds.) Lange Medical Publication, Los Altos, California (1976) 32-40.
Jornvall, et al.,Proc. Natl. Acad. Sci.-USA(Jan. 1982) 79(2):287-291.
Kao, et al.,J. Biol. Chem.(Oct. 5, 1992) 267(28):20239-20247.
Martin, et al.,Cancer Research(Apr. 1986) 46:2189-2192.
Nawroth, et al.,J. Exp. Med.(Aug. 1988) 168:637-647.
Noguchi, et al.,Biochemical and Biophysical Research Communications(Apr. 14, 1989) 160(1):222-227.
Robins, et al.,Immunology in Plant Sciences(1986) Linskens, et al. (Eds.) Springer-Verlag, New York, 86-141; and.
Suffness, et al.,J. Natural Products(1982) 45:1-14.
Clauss Matthias
Kao Janet
Kayton Mark
Libutti Steven K.
Stern David M.
Cooper & Dunham LLP
Huff Sheela
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Endothelial monocyte activating polypeptide II: a mediator... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endothelial monocyte activating polypeptide II: a mediator..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelial monocyte activating polypeptide II: a mediator... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2551141